Boyapati A, et al. High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response. ACR 2018, abstract L08.
Checkpointremmer-geïnduceerde inflammatoire artritis ook na stoppen immuuntherapie
apr 2020 | Artritis, Dermato-oncologie, Immuuntherapie, Longoncologie